Achillion Pharmaceuticals

Achillion is a science-driven, patient-focused company leveraging its strengths across the continuum from discovery to commercialization to provide better treatments for people with serious diseases. We use a highly-disciplined, scientifically rigorous, patient-focused approach across the continuum from discovery to patient care to discover and develop innovative medicines. Our prolific and sustainable discovery engine for potent and specific small-molecule drug candidates has produced breakthroughs for chronic hepatitis C (HCV) infection and a novel platform for the treatment of complement-mediated diseases. We have generated three clinical-stage, oral HCV candidates and a proprietary library of greater than 1,000 small molecule factor D inhibitors. Achillion is rapidly becoming a fully-integrated commercial pharmaceutical company as it advances the complement platform and prepares to bring life saving medicines to patients with rare diseases.
Company Growth (employees)
New Haven, US
Size (employees)
81 (est)+3%
Achillion Pharmaceuticals was founded in 1998 and is headquartered in New Haven, US

Achillion Pharmaceuticals Office Locations

Achillion Pharmaceuticals has an office in New Haven
New Haven, US (HQ)
300 George St

Achillion Pharmaceuticals Data and Metrics

Achillion Pharmaceuticals Financial Metrics

Achillion Pharmaceuticals's revenue was reported to be $15 m in FY, 2016 which is a 77% decrease from the previous period.

Revenue (FY, 2016)

15 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(61.7 m)

EBIT (FY, 2016)

(64.9 m)

Market capitalization (20-Jul-2017)

590.6 m

Closing share price (20-Jul-2017)


Cash (31-Dec-2016)

77.3 m


514 m
Achillion Pharmaceuticals's current market capitalization is $590.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


66.1 m15 m

Revenue growth, %


R&D expense

46.7 m53.5 m

General and administrative expense

12.7 m15.9 m

Operating expense total

59.5 m69.4 m81.2 m79.9 m


(59.5 m)(69.4 m)(441.9 m)(64.9 m)

EBIT margin, %


Interest expense

52 k37 k55 k68 k

Interest income

582 k455 k1.2 m3.2 m

Net Income

(58.9 m)(69 m)(441.9 m)(61.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


33.5 m73.7 m81.7 m77.3 m

Accounts Receivable

223.2 m


2.5 m1.9 m2.7 m3.5 m

Current Assets

124.8 m154.9 m462.6 m382.5 m

Total Assets

162.4 m156.8 m464.5 m413.9 m

Accounts Payable

4.6 m6.4 m4.1 m7 m

Total Debt

347 k474 k454 k652 k

Current Liabilities

9.4 m13.1 m14.7 m14 m

Total Liabilities

14.4 m

Additional Paid-in Capital

534.5 m599.8 m905.3 m916.6 m

Retained Earnings

(381.7 m)(450.7 m)(455.7 m)(517.4 m)

Total Equity

153 m143.5 m449.6 m399.5 m

Debt to Equity Ratio

0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

1.1 x1.1 x1 x1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(58.9 m)(69 m)(5 m)(61.7 m)

Depreciation and Amortization

399 k489 k694 k955 k


(104 k)575 k(837 k)(721 k)

Accounts Payable

315 k1.8 m(2.3 m)2.7 m

Cash From Operating Activities

(53.6 m)(55.5 m)5.6 m(65.7 m)

Purchases of PP&E

(408 k)(947 k)(704 k)(2.5 m)

Cash From Investing Activities

(65 m)43.3 m(298.7 m)60.7 m

Long-term Borrowings

(350 k)(313 k)(249 k)(246 k)

Cash From Financing Activities

133.6 m52.4 m301.1 m520 k

Interest Paid

46 k35 k50 k46 k
USDY, 2016


-7.9 x


-7.8 x


189.9 k

Financial Leverage

1 x

Achillion Pharmaceuticals Market Value History

Achillion Pharmaceuticals Online and Social Media Presence

Achillion Pharmaceuticals Company Life and Culture

You may also be interested in